TABLE 2.
Targetable receptors in adipose tissue and their actions and limitations.
Receptor | Beneficial action | Actions on thermogenic adipose tissue | Potential mechanism | Reasons for their limitation |
---|---|---|---|---|
β2/β3-Adrenergic receptors | Agonism | Increase BAT activation; induce beiging | Activate cAMP/PKA signaling; co-express with UCP1 | Side effects such as cardiovascular dysfunction |
A2A/A2B adenosine receptors | Agonism | Increase BAT activation and induce beiging | Heterodimerization of A2B and A2A receptors | Uncertain |
PPARα/β/γ/δ | Agonism | Regulates BAT biology; induces beiging; counters against HFD-induced BAT whitening | Cooperates with PGC-1α and PRDM16; activates the thermogenic pathway and enhances lipolysis; activates fatty acid oxidation | Weight gain effect; side effects such as hepatotoxicity, myocardial infarction, bladder cancer, and heart failure |
Glucocorticoid/mineralocorticoid receptors | Antagonism | Prevent HFD-induced lipid accumulation in BAT, decrease fat mass and body weight; induce beiging; enhance BAT function | UCP1 “unmasking” | Antagonism on androgen and progesterone receptors; risk of hyperkalemia |
Thyroid hormone receptors | Agonism | Induce beiging and promote adaptive thermogenesis; induce BAT proliferation | Crosstalk between thyroid hormone receptor signaling and β-adrenergic receptor signaling; promote progenitor cell proliferation | Uncertain |